Opioid-Free Total Shoulder With Suzetrigine
Open the official record
This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07938840. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Opioid-Free Postoperative Analgesia With Suzetrigine Following Total Shoulder Arthroplasty: A Prospective Randomized Controlled Noninferiority Trial
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This prospective, randomized, unblinded, controlled noninferiority study may benefit patients by determining whether an opioid-free postoperative analgesic pathway utilizing suzetrigine can provide adequate pain control following primary anatomic or reverse total shoulder arthroplasty compared with a standard opioid-containing pathway. If effective, this strategy may reduce or eliminate routine postoperative opioid use and associated adverse effects while maintaining patient satisfaction and adequate pain control. More broadly, this study will provide prospective data regarding the effectiveness and safety of suzetrigine following total shoulder arthroplasty and may help inform future opioid-free postoperative pain management protocols.
Study identification
- NCT ID
- NCT07938840
- Recruitment status
- Not yet recruiting
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 52 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 1, 2026 (Estimated)
- Primary completion
- Dec 31, 2027 (Estimated)
- Completion
- Dec 31, 2028 (Estimated)
- Last update posted
- Nov 16, 2026
2026 – 2028
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| OrthoCarolina Research Institute | Charlotte | North Carolina | 28207 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07938840, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 16, 2026 · Synced Nov 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.